[The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency].

Objective: To study the efficacy and safety of complex treatment with 2-ethyl-3-hydroxy-6-methylpyridine (mexidol forte 250) and venotonic drugs L-lysine aescinat and diosmin/hesperidin in patients with chronic cerebral venous insufficiency (CCVI).

Material And Methods: One hundred and twenty CCVI patients with clinical and ultrasonic signs of cerebral venous discirculation were studied. Patients were stratified into group 1 (=40) treated perorally with mexidol forte 250 and diosmin/hesperidin during 74 days in combination with two courses of L-lysine aescinat intravenously on the 1 and 30 days from baseline, group 2 (=40) treated with mexidol forte 250 and diosmin/hesperidin during 74 days, group 3 (=40) treated perorally with diosmin/hesperidin during 74 days.

[Treatment of chronic cerebral venous insufficiency: a study on an effect of L-lysine aescinat].

Aim: To study an effect of L-lysine aescinat on the dynamics of complaints, severity of neurological syndromes and parameters of cerebral blood flow estimated by transcranial doppler and duplex scanning in patients with chronic cerebral venous insufficiency (CCVI).

Material And Methods: Eighty patients with ultrasound-confirmed CCVI were examined. The basic group included 40 patients who received two treatment courses (intravenous drop-by-drop/stream introductions of L-lysine aescinat in the dose of 5ml during 7 days in 2nd and 30th days of examination).

[The epidemiological features of concomitance of diabetes mellitus and pulmonary tuberculosis].

The study was undertaken to reveal the clinical and epidemiological features of development diabetes mellitus (DM) and pulmonary tuberculosis (PT) in comorbidity. The material of the study was 143 case histories and outpatient cards of patients with DM and PT who were registered in 2001-2006. A total of 11,702 cases of tuberculosis were notified in 1999-2005.